Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

25 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Drug-Related Pneumonitis Induced by Osimertinib as First-Line Treatment for Epidermal Growth Factor Receptor Mutation-Positive Non-Small Cell Lung Cancer: A Real-World Setting.
Sato Y, Sumikawa H, Shibaki R, Morimoto T, Sakata Y, Oya Y, Tamiya M, Suzuki H, Matsumoto H, Yokoi T, Hashimoto K, Kobe H, Hino A, Inaba M, Tsukita Y, Ikeda H, Arai D, Maruyama H, Hara S, Tsumura S, Sakata S, Fujimoto D. Sato Y, et al. Among authors: shibaki r. Chest. 2022 Nov;162(5):1188-1198. doi: 10.1016/j.chest.2022.05.035. Epub 2022 Jun 1. Chest. 2022. PMID: 35661746
Osimertinib as first-line treatment for advanced epidermal growth factor receptor mutation-positive non-small-cell lung cancer in a real-world setting (OSI-FACT).
Sakata Y, Sakata S, Oya Y, Tamiya M, Suzuki H, Shibaki R, Okada A, Kobe H, Matsumoto H, Yokoi T, Sato Y, Uenami T, Saito G, Tsukita Y, Inaba M, Ikeda H, Arai D, Maruyama H, Hara S, Tsumura S, Morinaga J, Sakagami T. Sakata Y, et al. Among authors: shibaki r. Eur J Cancer. 2021 Dec;159:144-153. doi: 10.1016/j.ejca.2021.09.041. Epub 2021 Nov 5. Eur J Cancer. 2021. PMID: 34749119
Impact of pre-existing interstitial lung abnormal shadow on lung injury development and severity in patients of non-small cell lung cancer treated with osimertinib.
Shibaki R, Ozawa Y, Noguchi S, Murakami Y, Takase E, Azuma Y, Maebeya M, Sugimoto T, Hayata A, Hayakawa T, Tamaki S, Nakanishi M, Teraoka S, Akamatsu H. Shibaki R, et al. Cancer Med. 2022 Oct;11(20):3743-3750. doi: 10.1002/cam4.4750. Epub 2022 Apr 17. Cancer Med. 2022. PMID: 35434933 Free PMC article.
Association of immune-related pneumonitis with the presence of preexisting interstitial lung disease in patients with non-small lung cancer receiving anti-programmed cell death 1 antibody.
Shibaki R, Murakami S, Matsumoto Y, Yoshida T, Goto Y, Kanda S, Horinouchi H, Fujiwara Y, Yamamoto N, Kusumoto M, Yamamoto N, Ohe Y. Shibaki R, et al. Cancer Immunol Immunother. 2020 Jan;69(1):15-22. doi: 10.1007/s00262-019-02431-8. Epub 2019 Nov 19. Cancer Immunol Immunother. 2020. PMID: 31745589 Free PMC article.
Association between serum level soluble programmed cell death ligand 1 and prognosis in patients with non-small cell lung cancer treated with anti-PD-1 antibody.
Murakami S, Shibaki R, Matsumoto Y, Yoshida T, Goto Y, Kanda S, Horinouchi H, Fujiwara Y, Yamamoto N, Ohe Y. Murakami S, et al. Among authors: shibaki r. Thorac Cancer. 2020 Dec;11(12):3585-3595. doi: 10.1111/1759-7714.13721. Epub 2020 Oct 27. Thorac Cancer. 2020. PMID: 33108686 Free PMC article.
Immune-Related Adverse Events by Immune Checkpoint Inhibitors Significantly Predict Durable Efficacy Even in Responders with Advanced Non-Small Cell Lung Cancer.
Akamatsu H, Murakami E, Oyanagi J, Shibaki R, Kaki T, Takase E, Tanaka M, Harutani Y, Yamagata N, Okuda Y, Furuta K, Sugimoto T, Teraoka S, Hayata A, Tokudome N, Ozawa Y, Mori K, Koh Y, Yamamoto N. Akamatsu H, et al. Among authors: shibaki r. Oncologist. 2020 Apr;25(4):e679-e683. doi: 10.1634/theoncologist.2019-0299. Epub 2019 Nov 19. Oncologist. 2020. PMID: 32297443 Free PMC article.
A phase II study of cisplatin plus vinorelbine combined with atezolizumab as adjuvant therapy for completely resected non-small-cell lung cancer with EGFR mutation (West Japan Oncology Group 11719L/ADJUST study).
Shibaki R, Akamatsu H, Kato T, Nishino K, Okada M, Mitsudomi T, Wakuda K, Yoshimura K, Yamamoto N, Nakagawa K. Shibaki R, et al. Ther Adv Med Oncol. 2021 Jan 21;13:1758835920987647. doi: 10.1177/1758835920987647. eCollection 2021. Ther Adv Med Oncol. 2021. PMID: 33613698 Free PMC article.
CD24, not CD47, negatively impacts upon response to PD-1/L1 inhibitors in non-small-cell lung cancer with PD-L1 tumor proportion score < 50.
Ozawa Y, Harutani Y, Oyanagi J, Akamatsu H, Murakami E, Shibaki R, Hayata A, Sugimoto T, Tanaka M, Takakura T, Furuta K, Okuda Y, Sato K, Teraoka S, Ueda H, Tokudome N, Kitamura Y, Fukuoka J, Nakanishi M, Koh Y, Yamamoto N. Ozawa Y, et al. Among authors: shibaki r. Cancer Sci. 2021 Jan;112(1):72-80. doi: 10.1111/cas.14705. Epub 2020 Nov 27. Cancer Sci. 2021. PMID: 33084148 Free PMC article.
Predictive value of serum VEGF levels for elderly patients or for patients with poor performance status receiving anti-PD-1 antibody therapy for advanced non-small-cell lung cancer.
Shibaki R, Murakami S, Shinno Y, Matsumoto Y, Yoshida T, Goto Y, Kanda S, Horinouchi H, Fujiwara Y, Yamamoto N, Yamamoto N, Ohe Y. Shibaki R, et al. Cancer Immunol Immunother. 2020 Jul;69(7):1229-1236. doi: 10.1007/s00262-020-02539-2. Epub 2020 Mar 10. Cancer Immunol Immunother. 2020. PMID: 32152703 Free PMC article.
25 results